Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
Authors:
- Kathryn M. FieldKFKathryn M. Field
- John SimesJSJohn Simes
- Anna K. NowakANAnna K. Nowak
- Lawrence CherLCLawrence Cher
- Helen WheelerHWHelen Wheeler
- Elizabeth J. HoveyEHElizabeth J. Hovey
- Christopher S.B. BrownCBChristopher S.B. Brown
- Elizabeth H. BarnesEBElizabeth H. Barnes
- Kate SawkinsKSKate Sawkins
- Ann LivingstoneALAnn Livingstone
- Ron FreilichRFRon Freilich
- Pramit M. PhalPPPramit M. Phal
Open Access
- 30 June 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 17 (11) , 1504-1513
Abstract
The optimal use of bevacizumab in recurrent glioblastoma (GBM), including the choice of monotherapy or combination therapy, remains uncertain. The purpose of this study was to compare combination therapy with bevacizumab monotherapy. This was a 2-part randomized phase 2 study. Eligibility criteria included recurrent GBM after radiotherapy and temozolomide, no other chemotherapy for GBM, and Eastern Cooperative Oncology Group performance status 0–2. The primary objective (Part 1) was to determine the effect of bevacizumab plus carboplatin versus bevacizumab monotherapy on progression-free survival (PFS) using modified Response Assessment in Neuro-Oncology criteria. Bevacizumab was given every 2 weeks, 10 mg/kg; and carboplatin every 4 weeks, (AUC 5). On progression, patients able to continue were randomized to continue or cease bevacizumab (Part 2). Secondary endpoints included objective radiological response rate (ORR), quality of life, toxicity, and overall survival (OS). One hundred twenty-two patients (median age, 55y) were enrolled to Part 1 from 18 Australian sites. Median follow-up was 32 months, and median on-treatment time was 3.3 months. Median PFS was 3.5 months for each arm (hazard ratio [HR]: 0.92, 95% CI: 0.64–1.33, P = .66). ORR was 14% (combination) versus 6% (monotherapy) (P = .18). Median OS was 6.9 (combination) versus 7.5 months (monotherapy) (HR: 1.18, 95% CI: 0.82–1.69, P = .38). The incidence of bevacizumab-related adverse events was similar to prior literature, with no new toxicity signals. Toxicities were higher in the combination arm. Part 2 data (n = 48) will be reported separately. Adding carboplatin resulted in more toxicity without additional clinical benefit. Clinical outcomes in patients with recurrent GBM treated with bevacizumab were inferior to those in previously reported studies. ACTRN12610000915055.Keywords
This publication has 28 references indexed in Scilit:
- Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent GlioblastomaJournal of Clinical Oncology, 2013
- Carboplatin and bevacizumab for recurrent malignant gliomaOncology Letters, 2012
- Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastomaJournal of Neuro-Oncology, 2011
- A phase 2 trial of single‐agent bevacizumab given in an every‐3‐week schedule for patients with recurrent high‐grade gliomasCancer, 2010
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma MultiformeThe Oncologist, 2009
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- Bevacizumab Plus Irinotecan in Recurrent Glioblastoma MultiformeJournal of Clinical Oncology, 2007
- Epidemiology and molecular pathology of gliomaNature Clinical Practice Neurology, 2006
- A phase II study of intravenous carboplatin for the treatment of recurrent gliomasJournal of Neuro-Oncology, 1994